During carcinogenesis in rat liver by 3'-methyl-4-dimethylaminoazobenzene, the two moieties of the principal liver carcinogen-protein complex have considerably different turnover rates. With continued ingestion of the azocarcinogen by rats, the bound azo dye in the complex has a half-life of 2.5 ± 0.25 (SD) days, while the protein moiety has a half-life of 8.7 + 1.6 days (probability of identity <0.001). In addition, the interaction of the azocarcinogen with the principal target protein in vivo appears to extend the half-life of the protein itself from 3.3 i 0.2 days in normal liver to 8.7 i 1.6 days (P < 0.001). The slowing of the turnover of the protein by the carcinogen appears to be readily reversible, since soon after the cessation of azocarcinogen feeding, the half-life of the protein returns to that of the target protein in normal liver.
complex contains hydrophobicalfy bound activated azocarcinogen, whose specificity of reaction with critical macromolecule(s) in nuclei may be directed by the conformationally altered protein of an activated carcinogen-protein complex, i.e., a specific receptor protein containing activated azocarcinogen.
Chemical carcinogens either directly yield reactive electrophiles, or are enzymatically activated to that state. Despite their reactivity, sufficient amounts of the activated carcinogens somehow survive the presence of abundant intracellular nucleophiles, and interact covalently with unknown critical macromolecule(s) in causation of cancer (1, 2) .
A single liver protein appears to serve as the principal protein targett of the azocarcinogens throughout the duration of hepatocarcinogenesis in the rat (5) (6) (7) (8) . The resultant carcinogenprotein complex (h2 -5S azoprotein) is present in liver mainly in the cytosol (5) (6) (7) (8) , and in a small amount in nuclei (9, 10) .
Abbreviation: 3'-MeDAB, 3 '-methyl- 4-dimethylaminoazobenzene IN,N-dimethyl-p-(m-tolylazo)aniline].
* To whom reprint requests should be addressed. t The principal liver target protein of hepatic azocarcinogen was previously defined, in part, as the relatively basic normal protein that interacts with activated azocarcinogen to produce the principal carcinogen-protein complex (slow h2 -5S azoprotein) (3) . The designation of target protein is based on its and the principal carcinogen-protein adduct's identical immunoreactivity with specific antiserum, identical molecular charge, identical molecular size, and identical subunit size. No other protein in normal rat liver cytosol has been encountered with this combination of properties (4) .
When assayed after denaturation and proteolysis, the degraded protein apparently contains covalently bound azo dyes (5, 6, 8, 11) . However, speculation has been offered that the native complex may contain activated azocarcinogen (12 The biological turnover of the bound azo dye of the principal liver azoprotein was determined by measurement (see legend, Fig. 1 ) of the decrease in the specific activity of the azoprotein immunoprecipitated from the liver cytosols of rats injected with 3'-Me["4C]DAB (experiment 1). The dimethylaminophenyllabeled form of the carcinogen was chosen, in order to reduce the effects of the loss of label that might result from any possible enzymatic cleavage at the azo linkage after protein-binding of the carcinogen metabolite. Likewise, the biological turnover rate of the protein moiety of the principal liver azoprotein was assayed by measurement of the decrease in the specific activity of the principal azoprotein that was immunoprecipitated from the liver cytosols of rats injected with L-[guanido-14C]arginine (experiments 2 and 3). For the study of the turnover of liver proteins, arginine which is "4C-labeled in the guanido group is unique in that the probability of reincorporation of proteinderived label is small, because of the presence of high concentration of arginase in liver (16, 20) . (Fig. 1) .
The data indicate that the bound-dye moiety of the principal liver azoprotein had a half-life of 2.5 ± 0.25 (SD) days.
Turnover of the Protein Moiety of the Principal Liver Azoprotein. In experiment 2, the turnover of the protein of the azoprotein was examined in rats maintained on the carcinogenic diet. The protocol essentially matched that of experiment 1, except that L-[guanido-14C]arginine was injected instead of labeled carcinogen. After the administration of the "4C-labeled amino acid, the decrease in the specific activity of the immunoprecipitated protein was linear on a semilogarithmic plot to a degree reflected by a correlation coefficient of 0.952 (Fig. 1) . Fu(. 1 . The time-dependent decrease of the specific activity of labeled protein-bound azo dye and labeled protein of the principal liver carcinogen-protein complex during hepatocarcinogenesis by 3'-MeDAB. All rats were initially fed the azocarcinogen for 14 days. One group (experiment 1) was then administered single intraperitoneal doses of 3'-Me['4C]DAB (x--x), and fed the carcinogen until sacrifice. Two other groups were given L,-[guanido-j4Cjarginine intraperitoneally, followed by feeding of the azocarcinogen in experiment 2 (0-0), or control diet (A--A) in experiment 3. The liver cytosols, and specific immunoglobulins against the principal liver azoprotein, were clarified at 100,000 X g (average) for 30 min. Then 40,80, or 160 mg of cytosolic proteins was reacted with 12, 24, arnd 48 ml, respectively, of the gamma globulin solution for 1 hr at 21°, followed by 90 hr at 1-4°. After sedimentation at 100,000 X g for 45 min, the precipitates were washed twice in 12, 24, and 48 ml, respectively, and then in 5, 10, and 20 ml, respectively, of phosphate-buffered saline; dissolved in 0.01 M NaOH for aliquoting in the Lowry protein assay; then neutralized with 0.1 M HCl and lyophilized. The powders were dissolved in 1.0 ml of 88% formic acid, and the radioactivity was measured with 10 ml of Aquasol 2 (New England Nuclear Corp., Boston, MA) by means of (3-scintillation spectrometry.
per subunit) in the isolated mixture of complex and target protein (11) , and by the linearity of the plot in Fig. 1 The reversibility of the slowing of the protein-moiety turnover due to carcinogen was examined in experimnirlt 3. The rats were fed the azo dye for 14 days, inoculated with L-[guanido-14C]argirilne and thereafter fed the control diet. The loss of specific activity for the protein of the azoprotein was linear on a semilogarithmic plot up to 140 hr to a degree indicated by a correlation coefficient of 0.997 (Fig. 1) . Computed from the equation bf linear regression (Y =-0.00354X + 1.56), the protein had a half-life of 3.4 ± 0.2 (SD) days. It is noteworthy that this half-life is the same as that of the target protein of normal liver, i.e., 3.3 ± 0.2 days (4). These results and those in Fig. 1 indicate that the turnover of the protein moiety in this experiftent occurred via dissociation to the uncomplexed protein, that the dissociation was not rate limiting on the protein turnover, and that the dissociation essentially had occurred before hr 40 after cessation of carcinogen feeding (20 hr after []4Cjarginine administration). At least two-thirds of the level of complex present at 0 hr had apparently reverted to target protein by hr 140. It is unknown if the outlying value at 188 hr is spurious, or if it is from a low level of a slowly turning-over protein, e.g., one containing irreversibly (covalently) bound azo dye.
DISCUSSION
The principal carcinogen-protein complex (h2 -5S azoprotein) is composed of two moieties, protein and azo dye, with rather different turnover rates in rat liver during hepatocarcinogenesis by the aminoazo dyes. The bound carcinogen turns over at least 3.5-fold faster than does the protein moiety of the complex (P < 0.001). This significant difference, taken together with the reversible decrease in turnover of the protein moiety due to carcinogen, seems to be reasonably explained by a model of the native complex in which carcinogen is noncovalently bound to the protein and both moieties have separate biological activities (see the introduction).
Our evidence indicates that the carcinogen-protein complex may exist in two forms. In one form, the two moieties appear to be noncovalently held in vivo, yet, after protein denaturation, the complex has properties that are compatible with covalent bonding. The properties include withstanding electrophoresis in sodium dodecyl sulfate (11) , nonextraction of the bound dye by nonpolar solvents, but solubility in polar solvents after protein degradation (5, 6, 8) . This dual existence of the complex implies that the carcinogen in the native complex is in an activated state that is capable of yielding a reactive electrophile. It is noteworthy that the indications of the present biological investigation are in agreement with the results of an in vitro model study by J. Klinman of this institute (personal communication). The activated carcinogen, styrene epoxide (22, 23) , rapidly, reversibly, and noncovalently complexes with horse liver albohol dehydrogenase in its hydrophobic pocket (24) , while also reacting covalently at a slow rate.
The reversible reduction in the rate of turnover of the target protein, presumably due to its reversible combination with the azocarcinogen, resembles the known ligand-induced stabilization of other proteins in vivo and in vitro. Stabilization in vitro and protection against proteolytic degradation in vivo accompany complex formation between various ligands, e.g., substrates, cofactors, and prosthetic groups and their specific proteins, and between steroid hormones and their receptor proteins. The basis of these effects has generally been attributed to ligand-induced decreased frequency of "breathing" of polypeptide chains -in a more closed conformation (16 (5) (6) (7) (8) . The interaction, itself, has a high degree of specificity in regard to protein (5) (6) (7) (8) , carcinogen (7) , and organ (19) . The activated azocarcinowen appears to combine noncovalently with the target protein, thereby inducing a reversible conformational change to a more compact configuration. The complex is presumed to provide a necessary protection of 'the activated carcinogen in an intramolecular hydrophobic environment isolated from cellular nucleophiles during delivery to nuclei. A low concentration of the complex has been detected in liver cell nuclei (9, 10) . After a nuclear acceptor-induced conformational change, the complex, which is relatively basic (5, 8, 11 ), might provide a specificity essential for productive covalent interaction of activated carcinogen with critical macromolecule(s).
Considerable study will be required to determine whether, for carcinogenesis to occur, specific receptor proteins may necessarily protect activated carcinogens and facilitate their covalent interaction with critical macromolecule(s).
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